Biotech Values

[biomaven0]

SCTPF

Just one note of caution here - they are still quite a long way from the clinic on this project as it's a biologic and they haven't yet done the tox studies. So maybe 2015, putting them about a year behind Weissman.

Given the very low market cap they will basically have to either pretty much recapitalize the company or partner here.

Very thinly traded stock.

Peter